American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

Coronary calcium may predict a patient's risk of dying from noncardiac conditions
Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.
‘Unprecedented’: Single dose of new gene-editing therapy lowers cholesterol, triglycerides
First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.
Confirmed: AI software from Heartflow flags high-risk coronary plaques for cardiologists
Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.
New pill lowers cholesterol for patients already on statins—no needles required
The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine.
GLP-1 drugs and healthy lifestyle choices work in tandem to protect the heart
The rise of these medications continues to be one of the biggest stories in healthcare.

Coronary calcium may predict a patient's risk of dying from noncardiac conditions

Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.

‘Unprecedented’: Single dose of new gene-editing therapy lowers cholesterol, triglycerides

First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.

Confirmed: AI software from Heartflow flags high-risk coronary plaques for cardiologists

Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.

New pill lowers cholesterol for patients already on statins—no needles required

The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine.

GLP-1 drugs and healthy lifestyle choices work in tandem to protect the heart

The rise of these medications continues to be one of the biggest stories in healthcare.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.

New biodegradable PFO closure device shows early potential

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.

old woman or doctor shaking hands with patient

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.